Management attributes early success to real-world clinical performance matching trial data, with patients experiencing near-vision benefits within 30 minutes that last throughout the workday.

The launch strategy prioritizes a 'sample-first' approach to drive natural self-selection, which management believes creates a more durable, sticky patient base despite a more gradual initial NRx ramp compared to historical category launches.

Operational data indicates high productivity among top prescribers, with the top 1,000 doctors filling over 40% more scripts per doctor than the comparable VUITY launch period.

Management identified a 'mindset hurdle' where many ECPs initially viewed the product only for early presbyopes; strategic messaging is pivoting to highlight efficacy for moderate-to-advanced cases, LASIK patients, and contact lens wearers.

The company is leveraging a position of financial strength, ending 2025 with over $292 million in cash to fund a 33% expansion of the sales force to 117 representatives.

Strategic positioning focuses on the product as the only once-daily drop for a broad population of 128 million Americans, aiming to establish a new standard of care in a largely underpenetrated market.

Management expects a more meaningful impact on script volume in the second half of 2026 as the direct-to-consumer (DTC) campaign completes its typical two-quarter maturation cycle.

The sales force expansion to 117 reps is expected to be fully onboarded in Q2 2026, aiming to increase call frequency and reach approximately 15,000 ECPs.

Financial guidance assumes a steady gross-to-net ratio of approximately 90%, resulting in a consistent net cash per unit of $60 per monthly package.

The international strategy targets over 10 global regulatory submissions by the end of 2026, with potential approvals in multiple geographies anticipated in early 2027.

A pilot for linear TV advertising in select high-performing markets will launch in April 2026 to test consumer response and optimize the media mix beyond digital channels.

Q4 2025 net product revenues reached $1.6 million in the first partial quarter of launch, with over 20,000 monthly paid and filled prescriptions.

SG&A expenses increased 43% sequentially to $39.6 million, primarily driven by the establishment of the sales force and non-recurring investments for the Q1 2026 DTC launch.

R&D expenses decreased to zero in Q4 following the completion of Phase III trials and subsequent product approval, shifting the company's focus entirely to commercial execution.

Management confirmed a debt-free balance sheet with a quarterly cash burn rate expected to remain relatively flat throughout 2026.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management estimates over 90% of new patients receive a sample before their first prescription, which filters for those who find the product effective.

Early data shows patients transitioning from 1-month to 3-month supplies, which management views as a signal of high commitment and product satisfaction.

Management is actively countering the 'legacy' mindset that eye drops only work for early presbyopes by showing ECPs data that moderate-to-advanced patients often gain more lines of vision.

The sales force is training ECPs on a '10-second pitch' to integrate the product into routine exams for all eligible patients, including those with prior LASIK.

Website traffic is currently 5x higher than baseline, with spikes up to 10x during national activations, though management noted it takes time for awareness to convert to appointments.

While direct correlation from web click to script is not yet fully linked, early brand awareness lift on YouTube is performing 2x above industry benchmarks.

Management characterized their 117-rep expansion as a 'rationally sized' force compared to the roughly 300 reps used during the VUITY launch.

The team is seeing a significant number of 'NA' doctors—those who never prescribed VUITY—now adopting VIZZ, suggesting the product is expanding the total market rather than just trading share.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.